Tissue-engineered kidney disease models

DesRochers, Teresa M.; Palma, Erica; Kaplan, David L.

doi:10.1016/j.addr.2013.12.002

Cited by 78 publications

(59 citation statements)

References 137 publications

(218 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16], that intradialytic SBP variability is associated with greater dialytic fluid removal and with demographic characteristics such as older age. It is known that several factors contribute to intradialytic BP variability, including compromised autonomic nervous system and cardiovascular compensatory mechanisms [17]. Elderly patients have a lower tolerance for volume changes, which may be because of the higher morbidity from cardiac dysfunction and impaired vascular compliance.…”

Section: Discussionmentioning

confidence: 99%

Association of Age and BP Variability with Long-term Mortality in Hemodialysis Patients

Kim

Kang

Kim

et al. 2013

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Blood pressure (BP) variability is known as a poor prognostic factor for cardiovascular outcomes. This study assessed the prognostic significance of BP variability in association with increasing age in hemodialysis patients. Methods: We retrospectively analyzed 2,174 patients on hemodialysis from March 2005 to December 2012. The impact of intradialytic and interdialytic BP variability on all-cause mortality according to age groups was analyzed. Results: Kaplan-Meier survival curves for 5-year cumulative mortality showed higher mortality in patients with higher intradialytic systolic and diastolic BP variability as well as interdialytic systolic and diastolic BP variability (log-rank p=0.006, <0.001, 0.018 and < 0.001) in patients aged <55 years, but not in older age groups. Cox proportional analysis revealed that 5-year mortality was associated with intradialytic diastolic BP variability in patients aged <55 years (HR, 2.03 CI, 1.24-3.32). Conclusion: The overall mortality was associated with BP variability in patients aged <55 years, but not in older ages. This result suggests that younger hemodialysis patients with BP variability require further medical attention and intervention to reduce BP variability.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Age and BP Variability with Long-term Mortality in Hemodialysis Patients

Kim

Kang

Kim

et al. 2013

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…partially, has been attributed to the fact that cells grown in 2D culture lack the complex 3D tissue architecture and cell-cell or cell-extracellular matrix (ECM) interactions which exist in the body (12). These models therefore fail to fully reflect the pathophysiology of tumor cells, and the real level of resistance to radiation or drugs in the in vivo niche (6,13).…”

Section: Current Preclinical Tumor Modelsmentioning

confidence: 99%

Three‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)

Lv¹,

Hu²,

Lü³

et al. 2017

Oncol Lett

270

296

View full text Add to dashboard Cite

Abstract. In previous years, three-dimensional (3D) cell culture technology has become a focus of research in tumor cell biology, using a variety of methods and materials to mimic the in vivo microenvironment of cultured tumor cells ex vivo. These 3D tumor cells have demonstrated numerous different characteristics compared with traditional two-dimensional (2D) culture. 3D cell culture provides a useful platform for further identifying the biological characteristics of tumor cells, particularly in the drug sensitivity area of the key points of translational medicine. It promises to be a bridge between traditional 2D culture and animal experiments, and is of great importance for further research in the field of tumor biology. In the present review, previous 3D cell culture applications, focusing on anti-tumor drug susceptibility testing, are summarized.

show abstract

“…Over the last 10 years, despite a 62% increase in the number of drugs in development, it is estimated that only 1 in 10 drugs reaching clinical trials will ultimately be approved by the FDA [3]. Clinical trials can cost up to 2 billion dollars and may last up to 9 years on average with no guarantee of success [4,5]. It is reported that 3.5% of drugs approved in the US from 1980 to 2009 were forced to withdraw from the market due to safety concerns, with such decisions incurring huge financial losses [6].…”

Section: Introductionmentioning

confidence: 99%